Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for tough lung cancers: drug combo trial launches

NCT ID NCT05117242

Ongoing Disease control Sponsor: Genmab Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This trial tests a new drug called acasunlimab, either alone or combined with the cancer drug pembrolizumab, in people with advanced non-small cell lung cancer that has come back or stopped responding to standard treatments. About 125 adults will receive the drugs intravenously every 3 or 6 weeks for around 6 months. The goal is to see if the combination shrinks tumors and is safe.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER METASTATIC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER METASTATIC

Contacts and locations

Locations

  • Azienda Ospedaliera Universitaria Policlinico G Rodolico San Marco

    Catania, Italy

  • Cancer & Hematology Centers of Western Michigan CHCWM P.C.

    Grand Rapids, Michigan, 49503, United States

  • Centro Clinico Champalimaud

    Lisbon, Portugal

  • Centro Hospitalar Universitário do Porto - Hospital de Santo Antonio

    Porto, Portugal

  • Cheltenham General Hospital

    Cheltenham, United Kingdom

  • Clinica Universidad de Navarra

    Pamplona, Spain

  • Clinica Universidad de Navarra CUN

    Madrid, Spain

  • Department of Internal Medicine II

    Regensburg, Germany

  • Erasmus MC

    Rotterdam, Netherlands

  • Florida Cancer Center

    St. Petersburg, Florida, 33705, United States

  • Florida Cancer Specialists - FCS South

    Fort Myers, Florida, 33901, United States

  • Fundacion Instituto Valenciano de Oncologia

    Valencia, Spain

  • Gustave Roussy

    Villejuif, France

  • Henry Ford Cancer Institute

    Detroit, Michigan, 48202, United States

  • Hopital Charles Nicolle Chu Rouen

    Rouen, France

  • Hopital Morvan CHU de Brest

    Brest, France

  • Hopital dInstruction Des Armees Begin

    Saint-Mandé, France

  • Hospital Universitari Vall dHebron

    Barcelona, Spain

  • Hospital Universitario 12 de Octubre

    Madrid, Spain

  • Hospital Universitario Fundacion Jimenez Diaz

    Madrid, Spain

  • Hospital Universitario Virgen de la Victoria

    Málaga, Spain

  • Hôpital Foch

    Suresnes, France

  • IFO Regina Elena

    Roma, Italy

  • IRCCS Istituto Europeo di Oncologia

    Milan, Italy

  • Institut Bergonie

    Bordeaux, France

  • Institut de Cancerologie Strasbourg Europe (ICANS)

    Strasbourg, France

  • LKI Lungenfachklinik Immenhausen

    Immenhausen, Germany

  • La Maddalena SPA

    Palermo, Italy

  • Leids Universitair Medisch Centrum

    Leiden, Netherlands

  • MD Anderson Cancer Center

    Madrid, Spain

  • Maria Sklodowska-Curie National Research Institute of Oncology

    Warsaw, Poland

  • Med.Hochschule Hannover Klinik für Pneumologie

    Hanover, Germany

  • Medical College of Wisconsin

    Milwaukee, Wisconsin, 53226, United States

  • Netherlands Cancer Institute

    Amsterdam, Netherlands

  • Samodzielny Publiczny Zespol Gruzlicy i Chorob Pluc

    Olsztyn, Poland

  • St. Joseph Heritage Healthcare

    Santa Rosa, California, 95403, United States

  • The Christie Hospital

    Manchester, United Kingdom

  • UOC Oncoematologia AOU L.Vanvitelli

    Naples, Italy

  • Universitatsklinik Giessen und Marburg Standort Giessen

    Hessen, Germany

  • VU University Medical Center

    Amsterdam, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.